Novel Non-Crystalline Materials Analysis: New Strategies to De-risk Amorphous Material Formulation D
Publisher: Triclinic Labs, Inc
Access this content
Your content has been opened.
Novel Non-Crystalline Materials Analysis: New Strategies to De-risk Amorphous Material Formulation D has been emailed to . Entered the wrong email?
Don't see the content in your inbox?
Make sure to check your spam and other messages folders.
Can't get to your email right now?
To complete your registration and access this content, enter the sign-in code sent to your email.
Please enter a valid verification code.
Code sent to:
Register to access this content
By accessing content on the Pharmaceutical Manufacturing Resource Directory you agree to our Terms of Service and Privacy Policy; and, you acknowledge that your information may be shared with the content publisher.
The latest approaches for characterizing non-crystalline (amorphous) materials and determining physical stability under typical storage conditions. Amorphous forms consist of disordered arrangements of molecules that do not possess a distinguishable crystal lattice. Different forms of a drug substance can have different chemical and physical properties, including melting point, chemical reactivity, apparent solubility, dissolution rate, optical and mechanical properties, vapor pressure, and density. These properties can have a direct effect on the ability to process and/or manufacture the drug substance and the drug product, as well as on drug product stability, dissolution, and bioavailability. Instability of non-crystalline materials is of particular concern to regulatory bodies within companies and national agencies.
Similar content you might be interested in
